Official: Merck & Co to acquire Cubist for $8.4 billion
Confirming weekend speculation and rumors, US pharma giant Merck & Co (NYSE: MRK) this morning said it has entered into a definitive agreement to acquire biotech firm Cubist Pharmaceuticals (Nasdaq: CBST) for $102 per share in cash. This represents a 35% premium to Cubist’s average stock price for the most recent five trading days. Cubist’s shares surged 36% to $101.05 at 8 am in New York.
Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt and other considerations for a total transaction value of around $9.5 billion. Earlier rumors had suggested Merck would pay around $7 billion. The companies expect the transaction to close in the first quarter of 2015. This is Merck’s second acquisition in the past six month, the previous one being Idenix Pharmaceuticals for $3.85 billion.
Resurgence of interest in antibiotics
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze